nvax... che volumi

carpediem80

mai certezze
Registrato
23/7/02
Messaggi
1.707
Punti reazioni
88
...
 

Allegati

  • n.JPG
    n.JPG
    54,9 KB · Visite: 2.730

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
Wave Biotech Announces Strategic Alliance on Pandemic Influenza Vaccine Production Technologies
Monday October 17, 3:38 pm ET


SOMERSET, N.J., Oct. 17 /PRNewswire/ -- Wave Biotech, LLC, has announced today that the company is working with a number of worldwide pharmaceutical and biotech manufacturers that are making vaccines in the disposable Wave Bioreactor®. In its latest collaboration effort, Wave Biotech has entered into an agreement with Novavax, Inc. (Nasdaq: NVAX - News), based in Malvern, PA, and both companies will jointly collaborate on the development of a commercial scale production process for Novavax's pandemic influenza virus (avian flu) vaccine and other biological products. Wave Biotech will provide process and equipment expertise for the propriety technology based on disposable equipment for the manufacture of biologicals. The initial focus of the collaboration will be on Novavax's H5N1 avian-flu-Like Particle (VLP) vaccine. The joint collaboration will demonstrate in a production process that can express potent vaccine at high yield at the 500-liter scale.
ADVERTISEMENT


Vijay Singh, President and founder of Wave Biotech, LLC, issued the following statement: "Wave Biotech's disposable cell culture technology is an ideal fit for the Novavax application because it provides scalable technology that can be delivered, installed, and commissioned quickly for possible worldwide use."

Non Traditional Approach May Prove Necessary in the Race Against Time

Wave Biotech first began development on their innovative technology for the bioreactor six years ago, which may prove to be a critical component in the race to develop vaccines before a flu pandemic has an opportunity to occur. The company offers a quick way to rapidly manufacture and deploy bioreactors of up to 500 liters operating volume. Using large plastic bags as cell culture vessels, the bags are inflated, filled with culture nutrients, and inoculated with the cells of choice. These bags are placed on special machines that rock in a back and forth motion, generating waves that effectively aerate and mix the contents, thus producing a highly effective environment for cell growth and productivity. The machines have been fully operational since 1999, and are currently in use at almost every pharmaceutical or biotech company worldwide. They have been licensed as part of processes to produce human therapeutics and are built to comply with all applicable FDA guidelines. Most critically, they have a proven track record with many cell lines and viruses having been used for the production of proteins, viruses, gene therapy products, and vaccines. Due to the inexpensive and simple pre-sterilized disposable culture bag, cell culture can be carried out by low-tech labor without the need for extensive plant infrastructure. The rocking machines are mass-produced and can be delivered in weeks as compared to six months or longer for traditional stirred tank bioreactors.

Dr. Singh acknowledged that current issues concerning the possibility of an influenza pandemic striking humanity in the very near future is based on several notable factors. "First of all, the influenza virus is capable of mutating rapidly so that most people would have no significant resistance and would succumb. Additionally there is a disturbing increase in the occurrence of avian flu in Asia as well as the latest evidence in some of the eastern European countries. It is clear that the great influenza epidemic of 1918 was avian origin, followed by others in 1957 and 1968," he said. "Statistically," he continued, "another appears to be due at this time." He also noted that there are now anti-viral pharmaceuticals that may be useful in treating those people infected by the influenza virus, but he cautioned that the efficacy and availability of such drugs are very limited.

"The problem with influenza vaccines is that the virus mutates rapidly and a vaccine made against one strain will likely be useless against another one," said Singh. "Making such a vaccine is very time consuming and takes eight to ten months to build up a significant stockpile of doses."

The manufacturing equipment developed by Wave Biotech can be quickly configured and deployed anywhere in the world within days. The cells only contact a single-use bag and these bags can be stockpiled for up to three years providing an option for almost instant vaccine manufacturing. The equipment has been optimized over several years to enable easy operation with minimal training required. This method would enable vaccine facilities to be rapidly established anywhere in the world to combat the disease at the local level, thus preventing its release into the general population. The disposable cell culture bags can be manufactured in large quantities in simple factories using heat seaming equipment, delivered pre-sterilized by radiation and ready for use.

Engineered Baculovirus

Current vaccine manufacturers use 1950's chicken egg technology and other methods to make the vaccine. Singh considers these methods far more primitive because "even 350 million chicken eggs would only yield 300 million doses which would take at least six months to develop." Dr. Singh added, "This technology is not likely to save a significant number of people since compounding the problem is that if, indeed, the flu is avian origin, then where are the significantly large numbers of eggs needed to make the vaccine going to originate? The Spanish Flu epidemic of 1918 is estimated to have killed between 50 and 100 million people, at a time when world population was only 1.8 billion. Today we have 6.5 billion people and the impact of a virus such as the one in 1918 would clearly prove to be even more devastating."

Singh claims it is both necessary and critical for governments worldwide to secure alternative technologies to rapidly make an engineered cell line for vaccine production.

"One approach, developed by Novavax, is to identify the gene sequences of the virus as it exists now in the Far East and rapidly clone into baculovirus," said Dr. Singh. "This engineered baculovirus can be used to infect insect cells grown in liquid culture media and rapidly express large amounts of a suitable vaccine. This approach has been tested, proven and requires simple culture media that can be made from common chemicals. This way, it is possible to clone and develop a cell expressions system against a specific influenza strain within six weeks of securing the sample. While getting a cell line that produces the desired vaccine is only part of the story, in order to make sufficient quantities of the vaccine in such a time- sensitive manner, it will be essential to grow large numbers of cells using thousands of liters of cell culture capability."

OK!
 

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
Pre-Market Trade Reporting Tuesday October 18

Pre-Market
Last: $3.29 Pre-Market
Best Bid: N/A Pre-Market
High: $3.40
Pre-Market
Volume: 115,300 Pre-Market
Best Ask: N/A Pre-Market
Low: $3.20


Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08.10 $ 3.29 1500
08.10 $ 3.29 1000
08.09 $ 3.30 975
08.08 $ 3.28 100
08.08 $ 3.29 100
08.08 $ 3.29 100
08.08 $ 3.29 900
08.08 $ 3.26 500
08.07 $ 3.30 675
08.07 $ 3.30 2300
08.06 $ 3.30 1000
08.06 $ 3.26 1500
08.06 $ 3.26 500
08.06 $ 3.26 500
08.06 $ 3.26 400
08.06 $ 3.26 100
08.06 $ 3.26 500
08.05 $ 3.20 1000
08.05 $ 3.20 1000
08.05 $ 3.20 1000
08.05 $ 3.26 900
08.05 $ 3.26 100
08.05 $ 3.25 950
08.05 $ 3.26 500
08.05 $ 3.26 500
08.05 $ 3.27 800
08.05 $ 3.30 1000
08.05 $ 3.27 1000
08.05 $ 3.30 2000
08.05 $ 3.30 200
08.04 $ 3.27 4000
08.04 $ 3.28 100
08.04 $ 3.28 100
08.04 $ 3.28 300
08.04 $ 3.29 1100
08.04 $ 3.30 1000
08.04 $ 3.31 100
08.04 $ 3.31 900
08.04 $ 3.35 800
08.04 $ 3.35 600
08.04 $ 3.35 1000
08.04 $ 3.38 1000
08.04 $ 3.35 1000
08.04 $ 3.35 500
08.04 $ 3.35 100
08.04 $ 3.35 500
08.04 $ 3.34 200
08.04 $ 3.34 300
08.04 $ 3.29 800
08.04 $ 3.27 800
 

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
ad ora , .... volumi smisurati rispetto pure ieri
 

Magia

Nuovo Utente
Sospeso dallo Staff
Registrato
31/5/00
Messaggi
5.750
Punti reazioni
370
Ho l'impressione che stia per arrivare uno storno.
 

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
Magia ha scritto:
Ho l'impressione che stia per arrivare uno storno.

scattato lo stop a 3.25 ....

quale potrebbe essere un prezzo di ri-ingresso ?
 

Magia

Nuovo Utente
Sospeso dallo Staff
Registrato
31/5/00
Messaggi
5.750
Punti reazioni
370
zara ha scritto:
scattato lo stop a 3.25 ....

quale potrebbe essere un prezzo di ri-ingresso ?
Sono felice di esserti stato utile.
La prima cosa che ho imparato in borsa e quella di non innamorarmi mai dei titoli.
 

Magia

Nuovo Utente
Sospeso dallo Staff
Registrato
31/5/00
Messaggi
5.750
Punti reazioni
370
Fineco mi funziona da schifo, la adsl di alice mi funziona da schifo, ma cosa succede.

Non si può più lavorare!

Mi hanno rotto davvero le pall...
 

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
non sei l'unico .. magia ...
 

Magia

Nuovo Utente
Sospeso dallo Staff
Registrato
31/5/00
Messaggi
5.750
Punti reazioni
370
zara ha scritto:
non sei l'unico .. magia ...
Si, ma con queste condizioni è quasi impossibile operare.

Vedi cpth, segna 0,39$ invece trattava a 0,37$

Sono davvero degli stronz.. questi di Fineco.
Mi sa che la colpa e di Geronzi.
Se continuano in questa strada li mando a fare in cul...
 

pivello nasd400

Nuovo Utente
Registrato
6/11/03
Messaggi
1.839
Punti reazioni
73
In AH risale a 3.09 grazie alla news seguente

Novavax Completes ESTRASORB Partnership
Tuesday October 18, 5:31 pm ET


MALVERN, Pa., Oct. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) announced today that it has entered into a definitive license and supply agreement on ESTRASORB® (estradiol topical emulsion) with Esprit Pharma, a private specialty pharmaceutical company based in East Brunswick, NJ. Under the License Agreement, Esprit Pharma will obtain exclusive rights to market ESTRASORB in North America. Novavax will continue to manufacture ESTRASORB in its state-of-the-art pharmaceutical plant in Philadelphia. Esprit will pay Novavax a minimum cash consideration of $12.5 million, $2.0 million which was paid today, $8.0 million payable by year-end 2005, and the remaining balance of $2.5 million payable at the first anniversary of the Agreement in October 2006. Novavax will also receive a royalty on all net sales of ESTRASORB. Additionally, Esprit is obligated to pay Novavax certain milestone payments based on specific pre-determined net sales levels of ESTRASORB. This transaction today allows Novavax to continue to realize potential ESTRASORB marketing partnerships with other companies in international markets around the world.
 

Buffone

Mr Vaselina
Registrato
8/5/02
Messaggi
1.078
Punti reazioni
36
Io son dentro a 2,98. Vedendo il massimo odierno di 3,85 non credo di aver fatto un cattivo affare.E' il titolo del momento.Tenendo ben presente che da qua ad un paio di settimane la faccenda si ridimensionerà.
 

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
Buffone ha scritto:
Io son dentro a 2,98. Vedendo il massimo odierno di 3,85 non credo di aver fatto un cattivo affare.E' il titolo del momento.Tenendo ben presente che da qua ad un paio di settimane la faccenda si ridimensionerà.

After Hours Trade Reporting Tuesday October 18

After Hours
Last: $3.11 After Hours
Best Bid: N/A After Hours
High: $3.19
After Hours
Volume: 422,456 After Hours
Best Ask: N/A After Hours
Low: $2.83


After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18.29 $ 3.11 1000
18.29 $ 3.11 1000
18.28 $ 3.10 2500
18.28 $ 3.10 200
18.28 $ 3.08 100
18.27 $ 3.08 300
18.27 $ 3.08 700
18.26 $ 3.08 4000
18.26 $ 3.08 1000
18.25 $ 3.11 1000
18.23 $ 3.08 1100
18.23 $ 3.08 3600
18.23 $ 3.08 1000
18.23 $ 3.10 900
18.23 $ 3.10 1200
18.23 $ 3.10 1200
18.23 $ 3.10 500
18.23 $ 3.10 2000
18.21 $ 3.11 1000
18.20 $ 3.10 400
18.18 $ 3.10 300
18.18 $ 3.08 100
18.18 $ 3.10 100
18.18 $ 3.10 300
18.18 $ 3.06 100
18.18 $ 3.10 100
18.18 $ 3.10 100
18.18 $ 3.10 300
18.18 $ 3.06 100
18.18 $ 3.10 100
18.18 $ 3.10 1000
18.18 $ 3.10 300
18.18 $ 3.10 100
18.18 $ 3.10 100
18.18 $ 3.10 2000
18.18 $ 3.11 200
18.18 $ 3.11 1000
18.18 $ 3.11 100
18.18 $ 3.11 300
18.18 $ 3.12 3000
18.18 $ 3.11 100
18.18 $ 3.12 500
18.18 $ 3.11 100
18.18 $ 3.11 100
18.18 $ 3.12 200
18.17 $ 3.12 390
18.17 $ 3.12 2110
18.16 $ 3.12 500
18.15 $ 3.12 100
18.15 $ 3.13 190


questi sono gli ultimi scambi in after ...
 

Magia

Nuovo Utente
Sospeso dallo Staff
Registrato
31/5/00
Messaggi
5.750
Punti reazioni
370
3,19$ sono rientrato.

Non sono stato molto bravo, anzi tutt'altro.

Comunque la vendita era stata a 3,42$
 

zara

Oscar forever
Registrato
2/1/00
Messaggi
19.018
Punti reazioni
418
Magia ha scritto:
3,19$ sono rientrato.

Non sono stato molto bravo, anzi tutt'altro.

Comunque la vendita era stata a 3,42$

anche se ne ho poche in carico , aspetto .. a rischio di perdere il treno ... ora c'e' pure un gap aperto ... vediamo ...
 

Magia

Nuovo Utente
Sospeso dallo Staff
Registrato
31/5/00
Messaggi
5.750
Punti reazioni
370
zara ha scritto:
anche se ne ho poche in carico , aspetto .. a rischio di perdere il treno ... ora c'e' pure un gap aperto ... vediamo ...
Forse fai bene ad aspettare.

Io comunque ho messo una metà rispetto a prima.